Lupin’s Pithampur Unit 1 facility receives EIR from USFDA

06 Apr 2018 Evaluate

Lupin has received the Establishment Investigation Report (EIR) from US Food and Drug Administration (USFDA) for the successful inspection of its Pithampur, Unit 1.

The inspection was conducted in July 2017. The successful outcome of this inspection is encouraging, and further validates the company’s commitment of meeting global manufacturing standards.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.


Lupin Share Price

2089.40 -8.25 (-0.39%)
08-Dec-2025 11:14 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.35
Dr. Reddys Lab 1276.45
Cipla 1511.35
Zydus Lifesciences 932.95
Lupin 2089.40
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×